Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
How Far Are Surgeons from Surgical World Models? A Pilot Study on Zero-shot Surgical Video Generation with Expert Assessment
arXiv:2511.01775v1 Announce Type: cross Abstract: Foundation models in video generation are demonstrating remarkable capabilities as potential world models for simulating the physical world. However, their application in high-stakes domains like surgery, which demand deep, specialized causal knowledge rather than general physical rules, remains a critical unexplored gap. To systematically address this challenge, we present SurgVeo, the first expert-curated benchmark for video generation model e
-
Nature Biotechnology - Issue - nature.com science feeds
-
Scaling DNA synthesis with a microchip-based massively parallel synthesis system
Nature Biotechnology, Published online: 01 October 2025; doi:10.1038/s41587-025-02844-0A microchip-based DNA synthesis method enables scalable production of complex DNA constructs.
Scaling DNA synthesis with a microchip-based massively parallel synthesis system
Nature Biotechnology, Published online: 01 October 2025; doi:10.1038/s41587-025-02844-0
A microchip-based DNA synthesis method enables scalable production of complex DNA constructs.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Biomarkers associated with cancer-related anorexia in lung cancer: a scoping review
Support Care Cancer. 2025 Jun 19;33(7):596. doi: 10.1007/s00520-025-09670-9.ABSTRACTPURPOSE: Anorexia is a frequent and serious symptom in patients with lung cancer, often leading to malnutrition and cachexia, and negatively affecting quality of life and survival. This scoping review systematically synthesizes current evidence on biomarkers associated with cancer-related anorexia (CRA) in lung cancer, aiming to clarify biological mechanisms and inform targeted interventions.METHODS: We performed
Biomarkers associated with cancer-related anorexia in lung cancer: a scoping review
Support Care Cancer. 2025 Jun 19;33(7):596. doi: 10.1007/s00520-025-09670-9.
ABSTRACT
PURPOSE: Anorexia is a frequent and serious symptom in patients with lung cancer, often leading to malnutrition and cachexia, and negatively affecting quality of life and survival. This scoping review systematically synthesizes current evidence on biomarkers associated with cancer-related anorexia (CRA) in lung cancer, aiming to clarify biological mechanisms and inform targeted interventions.
METHODS: We performed a comprehensive literature search of studies evaluating the associations between CRA and various biomarkers in patients with lung cancer. Data were extracted and analyzed for pathway, genomic, transcriptomic, epigenetic, proteomic, metabolic, and composite biomarkers.
RESULTS: A total of 33 studies were included, identifying more than 100 biomarkers closely associated with CRA in lung cancer. These include inflammatory cytokines, energy metabolism markers, epigenetic and transcriptomic alterations, and disruptions in multiple cellular signaling pathways. Our analysis demonstrates that CRA is not the result of a single factor but reflects widespread dysregulation across metabolic, immune, and signaling networks. Some studies suggest that nutritional and anti-inflammatory interventions, such as n-3 fatty acid and antioxidant supplementation, can modulate biomarker profiles and potentially improve clinical outcomes.
CONCLUSION: CRA in lung cancer is a multifactorial syndrome involving complex interactions among inflammatory, metabolic, and signaling pathways. Multi-omics biomarker integration holds promise for early detection and individualized treatment, but larger, multi-center studies are needed to confirm clinical utility and optimize management strategies. Precision interventions based on biomarker profiles should be further explored in future research and practice.
PMID:40536584 | DOI:10.1007/s00520-025-09670-9
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703.ABSTRACTThe human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Per
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients
Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703.
ABSTRACT
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.
PMID:40073368 | PMC:PMC11907938 | DOI:10.18632/oncotarget.28703